Dianthus Therapeutics, Inc. /DE/ (DNTH) Free cash flow 2016–2022
Dianthus Therapeutics, Inc. /DE/ (DNTH) annual free cash flow history — operating cash flow minus capital expenditures, per SEC filings.
-$29.4MFY2022 · since FY2016: -$6.7M → -$29.4M
| Fiscal year | Value | YoY |
|---|---|---|
| FY2022 | -$29.4M | +51.7% |
| FY2021 | -$60.8M | +5.6% |
| FY2020 | -$64.4M | -7.1% |
| FY2019 | -$60.2M | -21.4% |
| FY2018 | -$49.6M | -102.6% |
| FY2017 | -$24.5M | -266.9% |
| FY2016 | -$6.7M | — |
Free cash flow = reported operating cash flow − reported capital expenditures for the same fiscal year.
Source: SEC XBRL filings · For reference only · Not investment advice
More DNTH financial trends
DNTH RevenueDNTH Net incomeDNTH Net marginDNTH Gross profitDNTH Gross marginDNTH Operating incomeDNTH Operating marginDNTH Operating cash flowDNTH Capital expendituresDNTH Return on equityDNTH Stock buybacksDNTH Dividends paidDNTH Total assetsDNTH Total liabilitiesDNTH Shareholders’ equityDNTH overview →